Infectious diseases now · 2026
Temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales: Is it a feasible option?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mamona-Kilu Christel, Hoang Bui Hai, Farfour Eric, Dinh Aurélien
Аннотация
BACKGROUND: Infections due to AmpC-producing Enterobacterales represent an increasing therapeutic challenge. Third-generation cephalosporins may select resistant mutants, inducing clinicians to use cefepime or carbapenems and thereby contributing to carbapenem resistance. While temocillin is a narrow-spectrum beta-lactam stable against AmpC enzymes, evidence of its impact in non-urinary tract infections remains limited.
METHODS: We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days.
RESULTS: Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events.
CONCLUSION: Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.
METHODS: We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days.
RESULTS: Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events.
CONCLUSION: Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.